|
MCE 国际站:Ramucirumab
中文名:雷莫芦单抗
CAS:947687-13-0
品牌:MedChemExpress (MCE)
存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性:Ramucirumab 是一种人类 VEGFR-2 拮抗剂,用于治疗实体瘤。 Ramucirumab 是一种重组人免疫球蛋白 G1 单克隆抗体,可结合 VEGFR-2 的细胞外结合域并阻止 VEGFR 配体:VEGF-A、VEGF-C 和 VEGF-D 的结合。 Ramucirumab 还是一种血管生成抑制剂[1][2]。 IC50 和靶标:VEGFR[2]
体外:Ramucirumab (10 μg/mL) 阻碍 VEGF 和肿瘤驱动的索形成[3]。Ramucirumab 不与小鼠 VEGFR2 发生交叉反应[3] .
热销产品:Bimekizumab | WM-8014 | 5'-Methylthioadenosine | Teriparatide | Prexasertib | p-SCN-Bn-DOTA | Palivizumab | Nicotinamide riboside (chloride) | CCR2 antagonist 1 | PDK4-IN-1 (hydrochloride)
研究领域:Protein Tyrosine Kinase/RTK
作用靶点:VEGFR
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
参考文献:[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.[2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.[3]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17;10(53):5523-5533.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-9-27 05:39
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社